|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytomorphologic features in thyroid nodules read as "suspicious for malignancy" on cytology may predict thyroid cancers with the BRAF mutation.
|
26187369 |
2015 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We strongly recommend preoperative evaluation of the BRAF V600E mutation in indeterminate thyroid nodules.
|
26020381 |
2015 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Herein, we tested 294 consecutive FNA samples from patients with thyroid nodules with the Real-Q BRAF V600E detection assay (Real-Q).
|
25937618 |
2015 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our aims were to evaluate the diagnostic utility of assessing the presence of BRAF and RAS mutations and RET/PTC1 and RET/PTC3 rearrangements in all cytological categories in an Italian group of thyroid nodule patients assessed prospectively, and to understand whether and which mutation testing might be helpful in cytologically indeterminate nodules.
|
25333496 |
2015 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In combination with BRAF mutation analysis, this predictive score closely correlated with the clinicopathological characteristics of the analyzed thyroid nodules.
|
25868389 |
2015 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CNB+BRAF(V600E) did not show significantly better diagnostic performance than CNB alone in thyroid nodules with previous AUS/FLUS results.
|
25978151 |
2015 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E detection is currently used as molecular test to improve the diagnosis of thyroid nodules, yet it lacks sensitivity.
|
26581891 |
2015 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we investigated the role of the BRAF(V600E) mutation as an additional study to cytology in diagnosing a thyroid nodule without suspicious US features.
|
24452872 |
2014 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For example, the analysis of BRAF, RAS and other mutations in cytological samples may help to distinction between follicular thyroid carcinoma and follicular thyroid adenoma and may significantly decrease the number of unnecessary surgery among patients with thyroid nodules.
|
24908232 |
2014 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V600E) assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay.
|
23775008 |
2014 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We recommend that patients with a thyroid nodule with any suspicious sonographic feature undergo preoperative BRAF(V600E) testing for risk stratification and to guide the initial surgical approach in PTC.
|
25337709 |
2014 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E mutation, common in papillary thyroid carcinoma (PTC), is helpful in fine needle aspiration diagnosis of thyroid nodules and is being evaluated for targeted therapies.
|
24746198 |
2014 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using pyrosequencing and quantitative methylation-specific PCR (Q-MSP) methods, FNABs from 79 and 38 patients with thyroid nodules in training and test groups, respectively, were analyzed for BRAF(V600E) mutation and gene methylation.
|
24588959 |
2014 |
|
Thyroid Nodule
|
0.100 |
Biomarker
|
disease |
BEFREE |
The BRAF assay was fully characterized by using plasmids and genomic DNA extracted from cell lines, metastatic colorectal cancer formalin-fixed, paraffin-embedded (FFPE) tissues, and thyroid nodule fine-needle aspirates.
|
23808402 |
2014 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The application of BRAF exon 15 analysis showed limitations when applied to discriminate thyroid nodules with indeterminate cytology if wild-type BRAF is found, and there is no role for avoiding diagnostic thyroid surgery.
|
25194426 |
2014 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found TERT promoter mutations in 0.0% (0/179) of benign thyroid nodules and 7.0% (9/129) of thyroid nodules of differentiated thyroid cancer, representing a 100% diagnostic specificity and 7.0% sensitivity, with the latter rising to 38.0% (49/129) when combined with BRAF V600E testing.
|
25121551 |
2014 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conducted a systematic review to evaluate the diagnostic value of testing for B-RAF(V600E) in thyroid nodules that are difficult to diagnose by FNA.
|
24167125 |
2014 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; galectin 3; and a new gene expression classifier, are outstanding examples that have improved diagnosis of thyroid nodules.
|
23668556 |
2013 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The BRAF(V600E) mutation analysis was a useful adjunctive diagnostic tool in the diagnosis of thyroid nodules with suspicious ultrasound features regardless of size.
|
23717622 |
2013 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In thyroid nodule fine-needle aspiration (FNA) cytology, the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category has a 5-15% malignancy risk that increases to 85-99% when mutation testing for BRAF, RAS, RET/PTC, or PAX8/PPARγ is positive.
|
24074409 |
2013 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The molecular tests on the thyroid nodule revealed the presence of BRAF-V600E mutation, but wild type BRAF in the ectopic tissue.
|
23200790 |
2013 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Detection of BRAF(V600E) in cytology specimens by pyrosequencing is a useful diagnostic adjunctive tool in the evaluation of thyroid nodules also in elderly subjects.
|
24267957 |
2013 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: a prospective case series of 960 patients.
|
23280049 |
2013 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Follow-up BRAF(V600E) mutation analysis may be helpful in the diagnosis of selected thyroid nodules negative for BRAF(V600E) mutation on initial analysis, which are assessed as suspicious malignant on US, diagnosed as non-diagnostic, benign or atypia on follow-up US-FNA.
|
23505540 |
2013 |
|
Thyroid Nodule
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?
|
23476074 |
2013 |